Navigation Links
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Date:7/10/2014

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma.

"We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," said J. Michael Pearson, chairman and chief executive officer.  "Humberto Antunes, CEO of Galderma, has embraced our commercial team and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
2. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
3. Valeant Pharmaceuticals To Present At Industry Conferences
4. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
5. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
6. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
7. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
8. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
11. Valeant Pharmaceuticals Announces Continuance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial ... 2017, and updated its financial outlook for fiscal 2017. ... fiscal third quarter, Hill-Rom reported earnings of $0.09 per ... the prior-year period. These results reflect after-tax special items, ... related to the non-cash write-down of assets associated with ...
(Date:7/27/2017)... Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results ... reported second quarter net sales of $1.954 billion, an ... an increase of 2.1% on a constant currency basis.  ... LDR Holding Corporation acquisition, second quarter 2017 revenues decreased ... on a constant currency basis. ...
(Date:7/26/2017)... 26, 2017 E.I. Medical Imaging (EIMI) has ... SharkLab to custom design the worlds first ultrasound system to be ... their native habitat. In preparation for a piece produced by ... Shark Week, Dr. Guttridge approached EIMI with the idea of ... to hammerhead sharks underwater. ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with another ... in a research study that focuses on family interactions when dealing with dietary restrictions. ... of adults who have gluten sensitivities who cohabitate with other adults who may or ...
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health and ... with pending recognition status from the Centers for Disease Control and Prevention (“CDC”) ... and live video conferencing. , The DPP resulted from clinical work conducted ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of ... location as an interventional pain management physician. He brings a wealth of pain ... migraine headaches, and significant experience in spinal cord stimulation for chronic pain. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... O'Fallon, MO (PRWEB) , ... August 18, 2017 , ... ... Charles County, is inaugurating a new charity drive to generate community support for efforts ... for research into cures and treatments for all types of cancer. , Each ...
Breaking Medicine News(10 mins):